The phase III ADAURA trial demonstrated that, in comparison to placebo, adjuvant osimertinib led to significantly longer overall survival among patients with completely resected, EGFR-mutated NSCLC (HR 0.49; 95%CI, 0.34-0.70) (2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.